Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the impact of the current COVID-19 pandemic on the treatment of patients with myeloproliferative neoplasms (MPNs), highlighting the reduced access to routine healthcare in the outpatient setting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).